Market closedNon-fractional
United Therapeutics/UTHR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About United Therapeutics
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Ticker
UTHR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Silver Spring, United States
Employees
1,168
Website
www.unither.com
UTHR Metrics
BasicAdvanced
$15B
Market cap
15.93
P/E ratio
$21.12
EPS
0.56
Beta
-
Dividend rate
Price and volume
Market cap
$15B
Beta
0.56
Financial strength
Current ratio
3.775
Quick ratio
3.503
Long term debt to equity
3.747
Total debt to equity
11.24
Interest coverage (TTM)
21.39%
Management effectiveness
Return on assets (TTM)
12.24%
Return on equity (TTM)
20.08%
Valuation
Price to earnings (TTM)
15.927
Price to revenue (TTM)
6.325
Price to book
2.81
Price to tangible book (TTM)
2.87
Price to free cash flow (TTM)
21.001
Growth
Revenue change (TTM)
26.09%
Earnings per share change (TTM)
41.95%
3-year revenue growth (CAGR)
18.38%
3-year earnings per share growth (CAGR)
33.01%
What the Analysts think about UTHR
Analyst Ratings
Majority rating from 16 analysts.
UTHR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$678M
10.25%
Net income
$307M
41.23%
Profit margin
45.24%
28.12%
UTHR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$5.24
$5.38
$4.36
$6.17
-
Expected
$4.51
$5.04
$4.19
$5.65
$6.24
Surprise
16.30%
6.69%
4.16%
9.18%
-
UTHR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for United Therapeutics stock?
United Therapeutics (UTHR) has a market cap of $15B as of July 27, 2024.
What is the P/E ratio for United Therapeutics stock?
The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 15.93 as of July 27, 2024.
Does United Therapeutics stock pay dividends?
No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next United Therapeutics dividend payment date?
United Therapeutics (UTHR) stock does not pay dividends to its shareholders.
What is the beta indicator for United Therapeutics?
United Therapeutics (UTHR) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell United Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.